A Phase 1/2 Study of DCC-3116 Plus Ripretinib for People with Advanced Gastrointestinal Stromal Tumor

Full Title

A Master Protocol for the Multi-Cohort, Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies

Purpose

Researchers want to find the best dose of DCC-3116 to give with ripretinib for people with gastrointestinal stromal tumor (GIST). The people in this study have GIST that has spread, even with treatment.

Ripretinib is a standard treatment for GIST. It targets proteins that affect cancer growth, which may slow or stop cancer spread. DCC-3116 targets molecules that prevent tumor cells from recovering from the damage from other anti-cancer treatments, such as ripretinib. Both drugs are taken orally (by mouth).

Contact

For more information and to see if you can join this study, please call Dr. Ping Chi’s office at 646-888-4166.